Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for Israeli Healthcare Professionals only

      Ubrelvy_homepage_banner

      RAPID

      Quick pain relief1
      Pain relief at 2 hours was demonstrated in 61.4% (UBRELVY 100 mg) vs 49.1% (placebo) when taken immediately or within 4 hours of onset3

      EFFECTIVE 

      Sustained pain freedom, return to function1-3
      Pain freedom at 2 hours (primary endpoint) was demonstrated in 21% (UBRELVY 100 mg) vs 13% (placebo). Sustained pain freedom from 2 to 24 hours (secondary endpoint) was achieved in 14% (UBRELVY 50 mg) vs 8% (placebo).1,2 64%-91% achieved normal function over 2-8 hours (UBRELVY 100 mg)4

      PROVEN SAFETY

      Adverse reactions similar to placebo1-3
      The safety profile for both doses allows patients to take UBRELVY anytime, anywhere.1-3 
      The most common adverse reactions were nausea (4% vs 2% placebo), somnolence (3% vs 1% placebo) and dry mouth (2% vs 1% placebo).1

      For more information please contact us, and our team will answer your questions

      Contact Us

      References:

      1. Ubrelvy Israel Prescribing information, July 2022.
      2. Lipton RB, Dodick DW, Ailani J, et al. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA. 2019;322(19):1887–1898.
      3. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230-2241.
      4. Data on file. Allergan.

      IL-UBR-220001 | September 2022